NCT06602232 - A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Alopecia AreataVitiligo

Interventions

DRUG

DR-01

DR-01 will be administered via IV infusion.

Trial Locations (20)

1010

RECRUITING

Dren Investigational Site, Grafton

2010

RECRUITING

Dren Investigational Site, Darlinghurst

2290

RECRUITING

Dren Investigational Site, Charlestown

3141

RECRUITING

Dren Investigational Site, South Yarra

4151

RECRUITING

Dren Investigational Site, Coorparoo

8013

RECRUITING

Dren Investigational Site, Christchurch

15213

NOT_YET_RECRUITING

Dren Investigational Site, Pittsburgh

19103

NOT_YET_RECRUITING

Dren Investigational Site, Philadelphia

30809

RECRUITING

Dren Investigational Site, Evans

33155

RECRUITING

Dren Investigational Site, Miami

37421

RECRUITING

Dren Investigational Site, Chattanooga

46250

RECRUITING

Dren Investigational Site, Indianapolis

47906

RECRUITING

Dren Investigational Site, West Lafayette

48084

RECRUITING

Dren Investigational Site, Troy

78215

RECRUITING

Dren Investigational Site, San Antonio

83642

RECRUITING

Dren Investigational Site, Meridian

91344

RECRUITING

Dren Investigational Site, Northridge

01605

NOT_YET_RECRUITING

Dren Investigational Site, Worcester

Unknown

RECRUITING

Dren Investigational Site, Fremantle

0632

RECRUITING

Dren Investigational Site, Auckland